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Abstract
Background: The appropriate level of oxygenation for extremely preterm neonates (<28 weeks’ gestation) to
maximise the greatest chance of survival, without incurring significant morbidity, remains unknown. Infants
exposed to lower levels of oxygen (targeting oxygen saturations of <90%) in the first weeks of life are at increased
risk of death, cerebral palsy, patent ductus arteriosus, pulmonary vascular resistance and apnoea, whilst those
maintained in higher levels of oxygen (targeting oxygen saturations of >90%) have been reported to have greater
rates of morbidity including retinopathy of prematurity and chronic lung disease. In order to answer this clinical
dilemma reliably, large scale trial evidence is needed.
Methods/Design: To detect a small but important 4% increase in death or severe disability in survivors, over 5000
neonates would need to be recruited. As extreme prematurity affects 1% of births, such a project undertaken by
one trial group would be prohibitively lengthy and expensive. Hence, the Neonatal Oxygenation Prospective
Meta-analysis (NeOProM) Collaboration has been formed. A prospective meta-analysis (PMA) is one where studies
are identified, evaluated, and determined to be eligible before the results of any included studies are known or
published, thereby avoiding some of the potential biases inherent in standard, retrospective meta-analyses. This
methodology provides the same strengths as a single large-scale multicentre randomised study whilst allowing
greater pragmatic flexibility. The NeOProM Collaboration protocol (NCT01124331) has been agreed prior to the
results of individual trials being available. This includes pre-specifying the hypotheses, inclusion criteria and
outcome measures to be used. Each trial will first publish their respective results as they become available and the
combined meta-analytic results, using individual patient data, will be published when all trials are complete. The
primary outcome to be assessed is a composite outcome of death or major disability at 18 months - 2 years
corrected age. Secondary outcomes include several measures of neonatal morbidity. The size of the combined
dataset will allow the effect of the interventions to be explored more reliably with respect to pre-specified patient-
and intervention-level characteristics.
Discussion: Results should be available by 2014.
Background
Extreme prematurity of less than 28 weeks’ gestation
affects approximately 1% of births [1]. Although 80% of
these infants are discharged home alive [2], they often
sustain severe morbidity [3], including chronic lung
disease, poor growth, respiratory illness, hospital re-
admissions, visual deficits, cerebral palsy, sensori-neural
disability and cognitive, educational and behavioural
impairment [4]. Recent studies have highlighted specific
health issues former very preterm infants may face in
later life, including an increased risk of cardiovascular
disease and hypertension, impaired glucose tolerance,
impaired renal function and abnormal respiratory func-
tion [5-9]. Very preterm infants account for a high pro-
portion of the costs and disability from neonatal
intensive care [10]. Reducing these morbidities would
enhance quality of life for these infants and benefit their
families and communities [11].
Oxygen is the most common therapy used in the care
of very preterm infants. It has been associated with
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disability [12]. However, preterm infants are highly sen-
sitive to the harmful biochemical and physiological
effects of supplemental oxygen. Toxic oxygen radicals
are increased in hyperoxaemia [13] and in re-oxygena-
tion after hypoxaemia. Preterm infants are vulnerable to
oxidative stress because they lack antioxidant protection
[13] from plasma radical scavengers such as beta- caro-
tene, antioxidant enzymes, such as glutathione peroxi-
dase, and their red cells lack superoxide dismutase.
Hyperoxaemia can constrict or obliterate vessels in an
immature eye and brain, causing ischaemic injury [13].
Of survivors born at less than 28 weeks’ gestation, 49%
have retinopathy of prematurity (ROP), 12.4% have
severe (Grade III or IV) ROP, 86% of these have surgery
[2], but about 10% of those treated become blind. New
recommendations have resulted in more infants with
severe ROP having laser surgery [14].
High inspired oxygen contributes to bronchopulmon-
ary dysplasia [15,16]. Oxidative damage to premyelinat-
ing oligodendrocytes in cerebral white matter is
proposed as a mechanism of periventricular leukomala-
cia [17] which has been correlated with cerebral palsy.
In preterm infants, oxygen reduces cerebral blood flow
velocity independently of the effects of hypocapnia or
hypotension [18].
Hyperoxaemia in the first eight days has been asso-
ciated with twice the odds of cerebral palsy at 2 years
[19]. In this study, the adjusted odds of cerebral palsy
increased eightfold for infants with the highest versus
t h el o w e s tq u i n t i l eo fe x p o s u r et oh y p e r o x a e m i a ,i n d i -
cating a dose-response effect. Importantly, hyperoxae-
mia was defined as arterial oxygen above 60 mm Hg,
in contrast with the long accepted upper limit of 80
mm Hg [20,21].
Less exposure to oxygen is a simple strategy that
could reduce oxidative stress and tissue injury and pre-
vent morbidity in very preterm infants. In healthy pre-
term infants breathing air, arterial oxygen saturation
(SpO2) is 85-98%. However, for infants requiring supple-
mental oxygen, the optimum range of arterial oxygen to
minimise organ damage, without causing hypoxic injury,
remains unknown.
Summary of existing evidence
The first case of ROP was reported in 1942. By 1954,
ROP had blinded about 10,000 infants [22,23]. In 1954-56,
three randomised trials, enrolling 341 infants, proved that
breathing unrestricted concentrations of inspired oxygen
was a major cause of ROP [24]. As arterial oxygen levels
were not able to be measured, the concentration of
inspired oxygen could not be targeted to meet each baby’s
needs. Following these findings, premature infants were
restricted to breathing less than 40% inspired oxygen in
order to prevent ROP. In the next 20 years over 150,000
premature babies died of hypoxic respiratory failure
[12,25-27]. It is estimated that for every infant whose sight
was saved, 16 died [12,22,24] and many others developed
spastic diplegia [26].
The Supplemental Therapeutic Oxygen for Prethres-
hold Retinopathy of Prematurity (STOP ROP) trial [28]
used pulse oximetry to target lower (89-94%) or higher
(96-99%) SpO2 in 649 preterm infants with pre-thresh-
old ROP. The higher range caused more adverse respira-
tory events, including pneumonia, chronic lung disease
requiring oxygen and diuretic therapy. There was no
statistically significant difference in the rate of progres-
sion to threshold ROP. In the Benefits of Oxygen
Saturation Targeting (BOOST) trial [29], 358 infants
b o r na tl e s st h a n3 0w e e k s ’ gestation were randomly
assigned, from 3 weeks or more after birth until they
breathed air, to target a SpO2 range of either 91-94% or
95-98%. This trial found no evidence that higher SpO2
targeting improved growth or development, but it did
increase days of oxygen therapy and use of health care
resources. Masked, adjusted oximeters were used in this
trial so that some were adjusted to display masked
values 2% lower than actual SpO2, and others displayed
masked values 2% higher. Staff were unaware of actual
SpO2 and targeted a masked range of 93-96%. The
authors concluded that further large randomised trials
were needed to determine how targeting different SpO2
levels from the day of birth affects ROP, chronic lung
disease, growth, disability and mortality [22,29].
An early cohort study, reported in 1977, was unable to
establish a relationship between arterial oxygen tension
(PaO2) and retinopathy [30]. A PaO2 range of 50-80
mm Hg became widely accepted as an appropriate level
to target [20,21,31], but was based on professional con-
sensus rather than evidence. A later study confirmed
that ROP occurred more often with longer periods of
time with a PaO2 above 80 mm Hg [32], but did not
determine if another limit was safer. Oximeters measur-
ing functional SpO2 display values about 1.5% higher
than those measuring fractional SpO2 [33]. Normal fetal
oxygen saturation is 70-80% [34]. In transposing oxygen
tensions of 50-80 mm Hg into equivalent arterial oxygen
saturation, most clinicians have targeted functional SpO2
90-95% (the mid range of what is considered physiologi-
cal) with a minimum of 85% [35].
In a more recent cohort study, Tin et al [34] showed
that lower SpO2 correlated with improved short term
respiratory and growth outcomes in infants born at less
than 28 weeks’ gestation. Babies in the neonatal inten-
sive care units (NICU) targeting SpO2 70-90% had ROP
surgery less often than those in the NICUs targeting
SpO2 88-98% (6.2% v 27.2%, 80% relative risk reduction
(RRR), p < 0.01). Survivors were ventilated less often
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postmenstrual age (18% v 46%, 61% RRR), and fewer
were below the 3rd centile for weight at discharge (17%
v 45%, 62% RRR) (all p < 0.01) while survival (52% v
53%) and cerebral palsy (15% v 17%) at one year were
similar [34].
Anderson et al [35] reported less Grade III/IV ROP
(2.4% v 5.5%, p < 0.001) and less ROP surgery (1.3% v
3.3%, 61% RRR, p < 0.037) in NICUs with functional
SpO2 upper limits of ≤92% vs >92%. Sun and colleagues
[36] studied 1544 infants weighing < 1000 g in NICUs
with upper SpO2 limits of ≤95% v >95%. NICUs with
≤95% upper limits had less Grade III ROP (10% v 29%),
surgery (4% v 12%, 67% RRR), chronic lung disease (27%
v 53%, 49% RRR) (all p < 0.001) and similar mortality
(17% v 24%). Chow et al [37] found that a functional
SpO2 of 83-90% was associated with less Grade III/IV
R O Pt h a na nS p O 2 of 90-98% in historical controls.
This study found that from 1998 to 2001, severe ROP
fell from 12.5% to 2.5% (80% RRR, p = 0.01) and ROP
surgery declined from 7.5% (6/80) to zero (0/188) (100%
RRR, p = 0.0006). These cohort studies thus suggest
that lower SpO2 may reduce ROP surgery by 61-100%;
chronic lung disease by 49-61%; and poor growth by
62%. Effects on mortality and long term sensori-neural
outcome remain unknown and could be beneficial or
harmful.
There are two opposing concerns. Less inspired oxy-
gen (targeting SpO2 < 90%) may increase patent ductus
arteriosus, pulmonary vascular resistance and apnoea,
and impair survival and neuro-development [38-40].
More inspired oxygen (targeting SpO2 >9 0 % )m a y
increase severe ROP and chronic lung disease
[16,34-37]. After recent studies [34-37], more NICUs
are adopting a lower SpO2 policy. This trend may
increase before the risks and benefits are determined.
The disastrous mistakes of the 1950s [16,18,23,25,27]
show how rapidly opinions can shift, destroying the
chance of obtaining reliable evidence.
Worldwide demands to resolve the dilemma are inten-
sifying. In 2003, an eminent international group of over
30 trialists, bio-statisticians, neonatologists, ophthalmol-
ogists and developmental paediatricians was convened
to conduct the NeOProM (Neonatal Oxygenation Pro-
spective Meta-analysis) Collaboration. In December
2003, the NeOProM project was outlined in a commen-
tary in Pediatrics [41].
There are five trials which are currently in progress to
assess this question (see Table 1). Each of these trials
will recruit between 300 and 1300 babies. However,
none individually will be able to exclude the possibility
that the expected valuable short term benefits associated
with giving babies less oxygen are not associated with a
small but significant 4% increase in death or serious
neurosensory disability in survivors, from an average
baseline of 42%. Reliably excluding a small, but clinically
important, difference in death or severe disability of 4%
requires over 5000 infants, which no single trial is able
to recruit in a timely fashion. For example the Austra-
lian BOOST II trial which plans to recruit approxi-
mately 1200 infants will be able to exclude a difference
of 8% (from 37% to 45% or from 37% to 29%) in the
major composite outcome of death or severe disability
in survivors.
For this reason, the Principal Investigators of the par-
ticipating trials have pledged their support for a pro-
spective meta-analysis (PMA) of individual patient data
(IPD) from each of these studies. These five trials are
sufficiently similar in terms of the population enrolled,
interventions tested and outcomes measured to allow
the collection and combination of IPD from each trial
into a large, core, common dataset. Combining the data
from several trials of similar design using PMA metho-
dology differs from a standard meta-analysis of trial
results in several important ways.
A prospective meta-analysis (PMA) is a meta-analysis
where studies (usually randomised controlled trials) are
identified, evaluated, and determined to be eligible
before the results of included studies are known or pub-
lished. This methodology can help avoid some of the
potential biases inherent in standard, retrospective
meta-analyses. These can include publication bias, selec-
tion bias of subjects and trials; and bias due to post hoc
selection of study questions, eligibility criteria, outcome
definitions or subgroups [42,43].
The key features of PMA are to prospectively define
and clearly specify the objectives, research question(s),
specific aims, hypotheses, subject eligibility criteria, sub-
groups, predictors, outcomes (primary and secondary)
and the analysis plans of eligible studies in advance of
knowing or publishing individual trial results [42]. PMA
provides more reliable estimates of treatment effects
through prospectively planned combined analysis of
large-scale randomised controlled trials. In addition to
having greater power to detect meaningful modest
differences in less frequent, clinically important outcomes,
PMA provides adequate power to evaluate events in
important subgroups underrepresented in smaller trials.
Thus, PMA provides the same strengths as a single large-
scale multicentre randomised study.
Another advantage is that PMA provides greater,
pragmatic flexibility in achieving the objectives of a sin-
gle mega-trial. Through prospectively planned combined
analysis of large, randomised trials, PMA accommodates
funding agency variations, reduces costs to an individual
funding agency for a mega-trial, whilst providing the
same strengths and benefits of a single large randomised
study. In this regard, PMA sets an important precedent
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mity in common protocol items amongst trials, includ-
ing data collection and outcome definitions, whilst
permitting flexibility in pre-specified protocol details
and funding regulations. To protect the integrity of each
individual trial, the main PMA results are published
only after the principal results of each individual trial
have been published. This methodology also has the
flexibility to allow questions to be added after the PMA
protocol has been developed provided the additional
studies or questions are chosen in a manner masked to
the results of included trials [42].
By establishing collaboration between trialists of the
eligible studies, it is possible to collect individual patient
data (IPD) and incorporate it into the meta-analysis.
Using data collected from each individual within a trial,
rather than relying on aggregate data from each trial,
can improve the power and scope of the meta-analysis.
In particular, a meta-analysis using IPD can enable
more flexible and detailed subgroup analyses [44,45].
This will be the first-ever neonatal prospective meta-
analysis. However, the methodology has been used
extensively in other areas of health care, particularly in
cardiovascular disease [43] and cancer [46]. Large PMAs
such as the Blood Pressure Lowering Treatment Trialists
Collaboration recently published [47] demonstrate how
this methodology can be used very effectively to assess
treatment effects in specific subgroups.
The Neonatal Oxygenation Prospective Meta-analysis
(NeOProM) Collaboration will be coordinated in
Sydney, Australia. The Principal Investigators of each of
the trials involved in NeOProM will be members of the
Collaboration’s Management Committee. Thus, this is
an opportunity to adapt the methodologies of prospec-
tive meta-analysis and individual patient data meta-ana-
lysis, already well-established in other health care fields,
for use in answering important neonatal questions.
Objectives
The primary question to be addressed by this study is:
does targeting a lower oxygen saturation range in extre-
mely preterm infants from birth or soon after, increase
or decrease the composite outcome of death or major
disability in survivors by 4% or more?
Hypotheses
Compared with a functional oxygen saturation level
(SpO2) of 91-95%, targeting SpO2 85-89% within 24
hours of birth is associated with <4% absolute risk dif-
ference from 42% [4,10] to 46% or from 42% to 38%
(10% relative risk increase or reduction (RRR)) in mor-
tality and major disability by 2 years corrected age
(defined as gestational age plus chronological age).
Sample size
A total sample size of 5230 (including infants from the
SUPPORT, BOOST II Australia, BOOST-NZ, BOOST II
UK, COT trials) (see Table 1 for trial details) would
have a 80% power to detect a 4% difference in the pri-
mary outcome: death or major disability. The precision
o ft h ec o m b i n e ds a m p l es i z ew i l le n s u r et h a ta4 %
increase in death or major disability could be detected
(for example from 42% to 46%), with 95% confidence
that the true result was an increase in this outcome
from 42% to between 43.7% and 48.7% (RR1.10, 95% CI
1.04-1.16).
Methods/Design
The Principal Investigators of all eligible trials were
approached and have agreed to participate in the NeO-
ProM Collaboration and provide the relevant individual
patient data upon completion of their respective trials.
A common data collection form, coding sheet and
detailed analysis plan will be developed and agreed by
members of the Collaboration prior to the collection
and analysis of data from the individual trials.
Eligibility criteria for studies to be included
Studies will be included if they are randomised trials.
The level of allocation concealment within each trial
will be assessed according to the criteria outlined in the
Cochrane Handbook [42], and only those trials with
adequate allocation concealment will be eligible. Partici-
pating trials are required to register on a publicly
Table 1 Eligible trials collaborating in the NeOProM initiative at December 2009
Trial
acronym
Country Planned
n
Recruitment start
date
Recruitment finish
date
Follow-up data
finalised
Planned date of publication
SUPPORT USA 1310 April 2005 April 2009 April 2011 May 2010 (short term outcomes)
Dec 2011 (longer term follow-up)
BOOST II Australia 1200 Mar 2006 Dec 2010 Dec 2012 May 2013
BOOST-NZ NZ 320 Sep 2006 Dec 2009 Dec 2011 Dec 2012
COT Canada 1200 Jan 2007 Jul 2010 Dec 2011 Jun 2012
BOOST II-UK UK 1200 Sep 2007 Feb 2011 Feb 2013 Sep 2013
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patient [44].
Participants
Participants in the eligible trials will be infants born
before 28 weeks’ gestation and enrolled within 24 hours
of birth.
Interventions
The intervention will be random assignment to either a
lower (SpO2 85-89%) or higher (SpO2 91-95%) functional
oxygen saturation target range from birth, or soon there-
after, for durations as specified in each trial protocol (see
Table 2). Intervention assignment must be masked to
parents, care-givers and outcome assessors by the use of
pulse oximeters that have been adjusted to display either
3 %a b o v eo rb e l o wt h ei n f a n t ’s actual saturation value,
within the 85-95% oxygen saturation range.
Outcomes
Analysis will be of all infants ever randomised and will be
based on intention-to-treat. Binary outcomes will be ana-
lysed using log-binomial regression models adjusting for
trial differences by including the trial variable in the model
specification. Exponentiating the parameter estimate for
treatment from a log-binomial regression model produces
a relative risk for treatment. Continuous normally distrib-
uted endpoints will be analysed using a linear fixed effects
model. Additionally the treatment by trial interaction will
be assessed to investigate possible heterogeneity of treat-
ment effects [48]. The overall estimated mean and stan-
dard deviation within each treatment group will be
presented along with the mean difference in treatment
effect and its 95% confidence interval with p value. If the
data do not meet the assumptions for the model then
transformations or alternative models will be investigated.
If appropriate, multivariable regression modeling will be
undertaken as exploratory analyses to assess treatment by
covariate interactions. A detailed analysis plan will be
developed as a separate document.
1. Primary outcome
￿ composite outcome of death or major disability by
18-24 months corrected age (gestational age plus
chronological age). Major disability is any of the fol-
lowing: Bayley III Developmental Assessment cogni-
tive score <85 and/or language score <85 [49],
severe visual loss (cannot fixate or is legally blind:
<6/60 vision, 1.3 logMAR in both eyes) [50], cerebral
palsy with Gross Motor Function Classification
S y s t e m( G M F C S )l e v e l2[ 5 1 ]o rh i g h e ro rM a n u a l
Ability Classification System (MACS) level 2 or
higher [52] at 18-24 months postmenstrual age, or
deafness requiring hearing aids.
2. Additional outcomes
￿ ROP treatment by laser photocoagulation or
cryotherapy (performed if Type I ROP or threshold
ROP occurs) [14]
￿ measures of respiratory support, defined as (a) sup-
plemental oxygen requirement at 36 weeks’ post-
menstrual age (see Table 2), (b) days of endotracheal
intubation (c) days of continuous positive airway
pressure (CPAP), (d) days of supplemental oxygen,
(e) days on home oxygen
￿ patent ductus arteriosus diagnosed by ultrasound
and requiring medical treatment
￿ patent ductus arteriosus requiring surgical
treatment
￿ necrotising enterocolitis requiring surgery
￿ weight at birth, 36 weeks’ postmenstrual age, dis-
charge home and 18-24 months corrected age
￿ re-admissions to hospital up to 18-24 months cor-
rected age
￿ cerebral palsy with GMFCS level 2 or higher or
MACS level 2 or higher at 18-24 months corrected
age
￿ blindness (<6/60 vision, 1.3 logMAR in both eyes)
￿ deafness requiring hearing aids
￿ quantitative Bayley III scores
￿ death
3. Planned subgroup analyses
The effect of the intervention (higher versus lower oxygen
saturation targeting) may be differential due to certain
characteristics of either the infant or the way the interven-
tion was delivered. These possible effects will be explored
by the following subgroup analyses.
a. Patient baseline characteristics
￿ gestational age (<26 weeks/>26 weeks)
￿ inborn or outborn status
￿ antenatal steroids (any: yes/no)
￿ gender (male/female)
￿ small for gestational age (yes/no)
￿ multiples (singleton/multiple)
￿ mode of delivery (vaginal/caesarean)
b. Intervention characteristics
￿ time of intervention commencement (<6 hours/
>6 hours)
￿ oximeter adjustment algorithm (original or
revised)
4. Planned sensitivity analyses
To assess whether results are robust to different meth-
ods of analysis and trial quality the following sensitivity
analyses will be conducted:
￿ comparison of analyses using random effects and
fixed effect models
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Ethics and management issues
Search methods for identification of studies
Efforts to identify any ongoing trials that may be eligi-
ble for participation in this PMA included searches for
published protocols on online databases such as
Medline and Embase as well as internet searches for
non-peer reviewed articles and other publications
using Google. Further efforts included informing net-
works of the proposed PMA and approaching presen-
ters at relevant conferences and network meetings.
Ongoing trials will only be permitted to join the PMA
prior to the results of any of the participating trials
being made publicly available.
Table 2 Characteristics of randomised trials included in NeOProM Collaboration
Trial
acronym
BOOST II-Australia BOOST II-UK BOOST-NZ SUPPORT COT
Registration
number
ACTRN12605000055606 ISRCTN00842661 ACTRN12605000253606 NCT00233324 ISRCTN62491227
Planned
sample size
1200 1200 320 1310 1200
Countries of
recruitment
Australia United Kingdom New Zealand United States Canada, USA, Argentina,
Germany, Israel, Finland
Participants Infants < 28 wks
gestation inborn or
outborn < 24 hrs old
Infants < 28 wks
gestation < 12 hrs old
(24 hrs if outborn)
Infants < 28 wks
gestation inborn or
outborn < 24 hrs old
Infants 24-27 wks
gestation < 2 hrs old
Infants 23 0/7-27 6/7 wks
gestation < 24 hrs old
Masked? Yes Yes Yes Yes Yes
Intervention Lower oxygen saturation
(85%-89%)
Lower oxygen saturation
(85%-89%)
Lower oxygen saturation
(85%-89%)
Lower oxygen saturation
(85%-89%)
Lower oxygen saturation
(85%-89%)
Comparator Higher oxygen saturation
(91%-95%)
Higher oxygen saturation
(91%-95%)
Higher oxygen saturation
(91%-95%)
Higher oxygen
saturation (91%-95%)
Higher oxygen saturation
(91%-95%)
Intervention
&
comparator
duration
Oximeter applied asap
after admission to NICU,
continued for minimum
2 wks. Thereafter
continued until 36 wks
corrected age or SpO2 >
96% in room air for 95%
of time over 3 days.
Oximeter applied from
randomisation until
postmenstrual age (PMA)
of 36 wks or until baby
is breathing air. All
monitoring at any time
prior to 36 wks to be
done using study
oximeter. BPD defined at
36 wks using a
physiological test.
Oximeter applied asap
after admission to NICU,
continued for minimum
2 wks. Thereafter
continued until 36 wks
corrected age or SpO2 >
96% in room air for 95%
of time over 3 days.
Oximeter applied within
2 hrs following
admission to NICU until
infant has been in room
air for 72 hrs or until 36
wks corrected age,
assessed by physiologic
oxygen test.
Oximeter applied from
day of birth until a
minimum 36 wks PMA. If
breathing room air
without any form of
respiratory assistance
from 35 wks PMA
onward, study oximetry
discontinued at a 36 wks
PMA. If receiving any
form of respiratory
assistance and/or oxygen
therapy from 35 wks
PMA onward study
oximetry continues until
40 wks PMA. Study
oximetry stopped at any
time before 40 wks PMA
if baby discharged home
(with or without
respiratory assistance
and/or oxygen).
Primary
outcome(s)
Death or survival with
major disability at 2 yrs
corrected for gestation.
Major disability defined
as having any of the
following:
* cognitive score <70 on
BSID-3
* severe visual loss
* cerebral palsy with
inability to walk at 2 yrs
* deafness requiring
hearing aids
Death or survival with
major disability at 2 yrs
corrected for gestation.
Major disability defined
as having any of the
following:
* cognitive score <70 on
BSID-3
* severe visual loss
* cerebral palsy with
inability to walk at 2 yrs
* deafness requiring (or
too severe to benefit
from) hearing aids
Death or survival with
major disability at 2 yrs
corrected for gestation.
Major disability is defined
as having any of the
following:
* cognitive score <70 on
BSID-3
* severe visual loss
* cerebral palsy with
inability to walk at 2 yrs
* deafness requiring
hearing aids
1. Death or survival with
neurodevelopmental
outcome at 18-22 mths
corrected age.
2. Survival without
severe ROP (threshold
ROP and/or the need for
surgical intervention)
Death or survival with
major disability at 18-21
mths Major disability
defined as having any of
the following:
* cognitive score <85
and/or language score
<85 on BSID-3
* severe visual loss
* cerebral palsy with
inability to crawl or walk
independently
* deafness requiring
hearing aids
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Because different oxygen targets may have competing
risks, it is essential that sufficiently large numbers of
recruits across all trials are allowed to accumulate to be
able to demonstrate net clinical benefit or harm. Each
participating trial will have its own Data and Safety
Monitoring Committee (DSMC). The Principal Investi-
gators of each trial will seek to ensure that the Chairper-
s o no ft h e i ro w nD S M Ck n o w so ft h ee x i s t e n c eo ft h e
other participating trials and their DSMC Chairpersons
so that communication can occur between them if
required. The NeOProM Management Committee will
give consideration to any requests from DSMC Chair-
persons for sharing of de-identified data (either aggre-
gate or individual patient data) should the need arise.
There are ‘in principle’ plans to update the PMA data at
regular intervals as longer term follow-up data become
available but (as of December 2009) there are no forma-
lised plans yet agreed.
Project management
Membership of the NeOProM Collaboration includes
representative(s) from each of the trials contributing
data to the project with an accompanying project coor-
dination and data management structure. An interna-
tional Steering Group has been established with all
collaborating trials being represented as well as experts
in the fields of PMA, IPD meta-analysis, data monitor-
ing and trial compliance and design being included. Pro-
ject coordination and data management/analysis are
coordinated from the NHMRC Clinical Trials Centre,
University of Sydney, Australia.
Funding
Funding for the NeOProM Collaboration has, and will
continue to be, sought from relevant funding agencies.
Each individual trial is receiving funding from their own
respective national government research funding bodies,
including the National Institutes of Health (United
States), National Health and Medical Research Council
(Australia), Health Research Council (New Zealand),
Medical Research Council (United Kingdom) and Cana-
dian Institutes of Health Research (Canada).
Publication policy
Each of the participating trials will be able to publish
their main individual trial results prior to publication of
the final PMA results. Each of the participating trials will
seek to include reference to the NeOProM Collaboration
in the published abstract and, if possible, in the text of
their main individual trial publication. The main manu-
script will be prepared by the NeOProM Steering Group,
before circulation to the full Collaborative Group for
comment and revision. Publications using these data will
be authored on behalf of the NeOProM Collaboration,
either with specific named authors, or on behalf of the
Collaboration as a whole, as agreed by the Steering
Group. Names of other participating Collaborators will
be acknowledged in an appropriate section of the manu-
script. Subsequent analyses and publications will only be
undertaken via collaboration with, and with the approval
of, the NeOProM Collaboration Steering Group.
Ethical considerations
Parents of participants in the individual trials have pre-
viously consented to participation by their children in
their respective trial. The data for this project are to be
used for the purpose for which they were originally col-
lected and are available through an agreement between
all trialists of the NeOProM Collaboration. These trial-
ists remain the custodians of their original individual
trial data at all times and have the right to withdraw
some or all of their data from the analyses. Data are
provided on the stipulation that all trials have received
ethical clearances from their relevant bodies.
Discussion
Results should be available by 2014.
Abbreviations
NeOProM: Neonatal Oxygenation Prospective Meta-analysis; PMA:
prospective meta-analysis; ROP: retinopathy of prematurity; SpO2: arterial
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System; DSMC: Data and Safety Monitoring Committee.
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